Acumen Hypotension Prediction Index – EV1000 Clinical Platform vs Study Watch

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
Acumen Hypotension Prediction Index – EV1000 Clinical Platform
by Edwards Lifesciences
VS
Study Watch
by Verily

AI Verdict

Tool A is specifically designed for real-time prediction of hypotensive events in acute care settings, providing clinicians with a predictive index and insights into hemodynamic instability. In contrast, Tool B is a wearable device focused on continuous, multi-parameter physiological data collection for clinical research and remote monitoring. While both utilize AI for physiological insights, their primary applications and target environments differ significantly, with Tool A focused on acute intervention and Tool B on broader data collection for research and long-term monitoring.

Choose Acumen Hypotension Prediction Index – EV1000 Clinical Platform if…

Choose the Acumen Hypotension Prediction Index if your primary need is real-time, predictive analytics to proactively manage and prevent hypotensive events in acute care settings. This tool is ideal for anesthesiologists and critical care teams requiring continuous hemodynamic monitoring and actionable insights to guide immediate interventions during surgery or in the ICU.

View Acumen Hypotension Prediction Index – EV1000 Clinical Platform →

Choose Study Watch if…

Choose the Verily Study Watch if your focus is on collecting continuous, long-term physiological data for clinical research and developing AI-enabled precision health solutions. This prescription-only wearable is best suited for studies requiring non-invasive monitoring of parameters like ECG and heart rate over extended periods, with data processed and analyzed in a cloud platform.

View Study Watch →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Acumen Hypotension Prediction Index – EV1000 Clinical Platform Study Watch
Deployment On-premise (integrated with EV1000 clinical platform and HemoSphere advanced monitoring platform) The Study Watch is a wrist-worn, multi-sensor wearable device used for data collection in clinical trials. Data from the watch is encrypted and sent securely to the Verily Cloud using a USB syncing and charging cradle and a wireless connectivity bridge (Verily Study Hub).
FDA Status Cleared AI-estimated Cleared AI-estimated
HIPAA Yes AI-estimated Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Acumen Hypotension Prediction Index – EV1000 Clinical Platform

Tool A is integrated into existing clinical workflows via the HemoSphere/EV1000 platform, providing real-time, actionable insights and smart alerts for clinicians in acute care settings. Its intuitive interface is designed for immediate clinical decision support. Tool B, while easy for patients to wear, primarily serves as a data collection device for research, with healthcare professionals viewing data through a web portal that lacks analysis features, making its direct clinical usability for immediate intervention less pronounced.

Clinical Value

Acumen Hypotension Prediction Index – EV1000 Clinical Platform

Tool A offers direct and actionable clinical value by predicting hypotensive events up to 15 minutes in advance with high accuracy and has been shown to significantly reduce intraoperative hypotension when combined with a treatment protocol. Tool B provides valuable continuous physiological data for clinical research and the development of digital biomarkers for various conditions, but its immediate, direct clinical impact on patient management for acute conditions is less defined.

Pricing & Value

Acumen Hypotension Prediction Index – EV1000 Clinical Platform

Both tools lack transparent public pricing, making a direct cost comparison impossible. However, Tool A has demonstrated a clear potential for economic value by significantly reducing intraoperative hypotension, which can lead to decreased postoperative complications, shorter lengths of stay, and associated cost savings for healthcare providers. Tool B's value is primarily in enabling clinical research, which is valuable but harder to quantify in terms of direct operational cost benefits for a healthcare facility.

Enterprise Readiness

Acumen Hypotension Prediction Index – EV1000 Clinical Platform

Tool A, from Edwards Lifesciences, integrates seamlessly with established critical care monitoring platforms and is backed by 24/7 technical support, indicating strong enterprise readiness. While Tool B is from Verily Life Sciences (an Alphabet company) and is FDA cleared, it faces an ongoing whistleblower lawsuit alleging HIPAA violations and data misuse, which introduces significant risk and uncertainty for enterprise adoption.

Innovation

Acumen Hypotension Prediction Index – EV1000 Clinical Platform

Tool A demonstrates a more direct and mature application of AI by using machine learning to provide real-time predictive insights into impending hypotensive events and their root causes, directly aiding acute clinical decision-making. Tool B's innovation lies in its advanced multi-sensor wearable technology for unobtrusive, continuous data collection, which is foundational for enabling future AI-driven precision health solutions and digital biomarkers.

Support & Docs

Acumen Hypotension Prediction Index – EV1000 Clinical Platform

Edwards Lifesciences provides comprehensive support for Tool A, including 24/7 technical support for its HemoSphere platform and a dedicated service program for software updates and protection. While Verily provides a user manual for Study Watch and has conducted human factors assessments for its instructions for use, the explicit breadth and availability of ongoing technical support for its research-focused device are not as clearly detailed in the available information.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Acumen Hypotension Prediction Index – EV1000 Clinical Platform Study Watch
Product Name Acumen Hypotension Prediction Index u2013 EV1000 Clinical Platform Study Watch
Company Edwards Lifesciences Verily Life Sciences
Tagline Predicting and managing hypotension before it occurs. Powering AI-enabled precision health solutions that accelerate research and improve care for individuals and communities.
Primary Clinical Focus/Prediction Predicts hypotensive events up to 15 minutes in advance, providing clinicians with insights into hemodynamic instability and potential causes to help reduce intraoperative hypotension. Non-invasive, continuous physiological monitoring in clinical research, collecting data like ECG, heart rate, and movement for analysis in Verily's cloud platform.
Monitoring Capabilities Continuous hemodynamic monitoring; HPI Parameter (0-100 likelihood score); Smart Alerts for trending hypotension; Smart Trend screen; Relationship View screen (preload, afterload, contractility insights); Non-invasive (Acumen IQ cuff) and minimally-invasive (Acumen IQ sensor) options. Continuous physiological monitoring; Multiple physiological sensors (ECG, heart rate, electrodermal activity, inertial movements); On-demand single-channel ECG; Irregular pulse monitor.
Core Technology Machine learning-based algorithm for prediction. Sensor-based wearable device; Cloud-based data processing with algorithms and machine learning.

Videos

Demos, reviews, and walkthroughs featuring Acumen Hypotension Prediction Index – EV1000 Clinical Platform and Study Watch.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Acumen HPI is designed for real-time, continuous hemodynamic monitoring in acute care settings like the OR or ICU, providing immediate predictive insights and alerts to guide interventions. The learning curve would involve understanding the HPI parameter, Smart Alerts, and the Relationship View screen for proactive management. Verily Study Watch, a wearable, is primarily for continuous physiological data collection in clinical research or long-term monitoring, with data uploaded to a cloud platform for analysis. The learning curve would focus on patient onboarding for proper device use and staff understanding of data management and cloud-based analysis.
Acumen HPI integrates with Edwards Lifesciences' monitoring platforms, and while direct EHR integration specifics are not detailed, it is used in studies that involve automated extraction of device-captured data into EHRs. Verily Study Watch uploads collected physiological data to Verily's cloud platform, and integration with EHRs would likely occur through data export or APIs from this platform, supporting research and potentially informing care decisions.
Acumen HPI software accurately predicts hypotension up to 15 minutes in advance, with studies showing high sensitivity and specificity (e.g., 90% sensitivity and 89% specificity 10 minutes before an event) and a significant reduction in the duration and severity of intraoperative hypotension. This provides clinicians with actionable insights for proactive intervention. Verily Study Watch collects continuous physiological data like ECG and heart rate, with studies demonstrating its ability to accurately detect conditions such as atrial fibrillation and track sleep measures, supporting diagnostic insights and long-term monitoring in research.
Acumen HPI is best suited for anesthesiology, critical care, and emergency medicine, focusing on surgical and non-surgical patients requiring advanced hemodynamic monitoring to predict and manage hypotensive events. Verily Study Watch is designed for clinical research and remote monitoring in specialties like cardiology, neurology, and sleep medicine, collecting continuous physiological data for long-term studies and chronic condition management.
Verily Study Watch encrypts all data on the device before uploading it to Verily's cloud platform, which adheres to industry-recognized frameworks like SOC 2 Type II and ISO/IEC 27001, and implements strong encryption (in-transit and at-rest) and tightly restricted role-based access. For Acumen HPI, data integrity in clinical studies involves automated extraction into EHRs with quality checks, and duplicate files are maintained on secured and backed-up servers.
For Acumen HPI, clinical studies mention data entry procedures following standard operating procedures, data queries and resolution processes, and independent audits to confirm consistency among patient records, study data sheets, and the main database. Verily's platform, which processes Study Watch data, provides a Trusted Research Environment (TRE) with advanced access, governance, and collaborative analysis tools, implying robust audit-trail capabilities for data access and processing.
Deploying Acumen HPI across multiple sites would require integration with existing Edwards Lifesciences HemoSphere or EV1000 platforms and the deployment of dedicated Acumen IQ sensors or cuffs at each location. For Verily Study Watch, multi-site rollout involves distributing the wearable devices to patients, managing patient onboarding for proper use, and ensuring consistent data upload and access to the centralized cloud platform for analysis across all participating sites.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform
AISAP Cardio vs Rapid Enterprise Platform
AngioWaveNet vs Rapid Enterprise Platform
CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring Acumen Hypotension Prediction Index – EV1000 Clinical Platform or Study Watch

Backers

Who funded each tool's parent company.

Study Watch

AI Tool Finder
AI-powered search. Results may not be comprehensive.